Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

Radical hysterectomy with adjuvant radiotherapy versus radical radiotherapy for FIGO stage IIB cervical cancer

Authors: Yanlan Chai, Tao Wang, Juan Wang, Yunyi Yang, Ying Gao, Jiyong Gao, Shangfeng Gao, Yueling Wang, Xi Zhou, Zi Liu

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

The goal of this study was to compare treatment outcomes for Federation of Gynecology and Obstetrics (FIGO) stage IIB cervical carcinoma patients receiving radical surgery followed by adjuvant postoperative radiotherapy versus radical radiotherapy.

Methods

Medical records of FIGO stage IIB cervical cancer patients treated between July 2008 and December 2011 were retrospectively reviewed. A total of 148 patients underwent radical hysterectomy with pelvic lymph node dissection followed by adjuvant radiotherapy (surgery-based group). These patients were compared with 290 patients that received radical radiotherapy alone (RT-based group). Recurrence rates, progression-free survival (PFS), overall survival (OS), local control rates, and treatment-related complications were compared for these two groups.

Results

Similar rates of recurrence (16.89% vs. 12.41%, p = 0.200), PFS (log-rank, p = 0.211), OS (log-rank, p = 0.347), and local control rates (log-rank, p = 0.668) were observed for the surgery-based group and the RT-based group, respectively. Moreover, the incidence of acute grade 3–4 gastrointestinal reactions and late grade 3–4 lower limb lymphedema were significantly higher for the surgery-based group versus the RT-based group. Cox multivariate analyses found no significant difference in survival outcome between the two groups, and tumor diameter and histopathology were identified as significant prognostic factors for OS.

Conclusions

Radical radiotherapy was associated with fewer treatment-related complications and achieved comparable survival outcomes for patients with FIGO stage IIB cervical cancer compared to radical hysterectomy followed by postoperative radiotherapy.
Appendix
Available only for authorised users
Literature
1.
Kasamatsu T, Onda T, Sawada M, Kato T, Ikeda S: Radical hysterectomy for FIGO stage IIB cervical cancer: clinicopathological characteristics and prognostic evaluation. Gynecol Oncol. 2009, 114: 69-148. 10.1016/j.ygyno.2009.03.026.CrossRefPubMed
2.
3.
Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, Heintz AP, Ngan HY, Pecorelli S: Carcinoma of the cervix uteri. Int J Gynaecol Obstet. 2003, 83 (Suppl 1): 41-78.CrossRefPubMed
4.
Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, Favini G, Ferri L, Mangioni C: Randomised study of radical surgery versus radiotherapy for stage Ib–IIa cervical cancer. Lancet. 1997, 350: 535-540. 10.1016/S0140-6736(97)02250-2.CrossRefPubMed
5.
Undurraga M, Loubeyre P, Dubuisson JB, Schneider D, Petignat P: Early-stage cervical cancer: is surgery better than radiotherapy?. Expert Rev Anticancer Ther. 2010, 10: 451-460. 10.1586/era.09.192.CrossRefPubMed
6.
Suprasert P, Srisomboon J, Kasamatsu T: Radical hysterectomy for stage IIB cervical cancer: a review. Int J Gynecol Cancer. 2005, 15: 995-1001. 10.1111/j.1525-1438.2005.00259.x.CrossRefPubMed
7.
Yamashita H, Nakagawa K, Tago M, Shiraishi K, Nakamura N, Ohtomo K, Oda K, Nakagawa S, Yasugi T, Taketani Y: Comparison between conventional surgery and radiotherapy for FIGO stage I–II cervical carcinoma: a retrospective Japanese study. Gynecol Oncol. 2005, 97: 834-839. 10.1016/j.ygyno.2005.03.017.CrossRefPubMed
8.
Ohara K, Sugahara S, Kagei K, Hata M, Igaki H, Tokuuye K, Akine Y: Retrospective comparison of clinical outcome between radiotherapy alone and surgery plus postoperative radiotherapy in the treatment of stages IB–IIB cervical squamous cell carcinoma. Radiat Med. 2004, 22: 42-48.PubMed
9.
Mabuchi S, Okazawa M, Isohashi F, Matsuo K, Ohta Y, Suzuki O, Yoshioka Y, Enomoto T, Kamiura S, Kimura T: Radical hysterectomy with adjuvant radiotherapy versus definitive radiotherapy alone for FIGO stage IIB cervical cancer. Gynecol Oncol. 2011, 123 (2): 241-247. 10.1016/j.ygyno.2011.07.009.CrossRefPubMed
10.
Rotman M, Sedlis A, Piedmonte MR, Bundy B, Lentz SS, Muderspach LI, Zaino RJ: A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study. Int J Radiat Oncol Biol Phys. 2006, 65 (1): 169-176. 10.1016/j.ijrobp.2005.10.019.CrossRefPubMed
11.
Small W, Mell LK, Anderson P, Creutzberg C, De Los SJ, Gaffney D, Jhingran A, Portelance L, Schefter T, Iyer R, Varia M, Winter K, Mundt AJ: Consensus guidelines for delineation of clinical target volume for Intensity-Modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer. Int J Radiat Oncol Biol Phys. 2008, 71 (2): 428-434. 10.1016/j.ijrobp.2007.09.042.CrossRefPubMed
12.
Oranusi CK, Nwofor A, Oranusi IO: Complication rates of open transvesical prostatectomy according to the Clavien–Dindo classification system. Niger J Clin Pract. 2012, 15 (1): 34-37. 10.4103/1119-3077.94094.CrossRefPubMed
13.
Park TK, Kwon JY, Kim SW, Kim SH, Kim SN, Kim GE: Patterns of treatment failure following radiotherapy with combination chemotherapy for patients with high-riskstage IIB cervical carcinoma. Int J Clin Oncol. 2004, 9 (2): 120-124. 10.1007/s10147-003-0378-9.CrossRefPubMed
14.
Einstein MH, Rash JK, Chappell RJ, Swietlik JM, Hollenberg JP, Connor JP: Quality of life in cervical cancer survivors: patient and provider perspectives on common complications of cervical cancer and treatment. Gynecol Oncol. 2012, 125 (1): 163-167. 10.1016/j.ygyno.2011.10.033.CrossRefPubMed
15.
Hsu WC, Chung NN, Chen YC, Ting LL, Wang PM, Hsieh PC, Chan SC: Comparison of surgery or radiotherapy on complications and quality of life in patients with the stage IB and IIA uterine cervical cancer. Gynecol Oncol. 2009, 115 (1): 41-45. 10.1016/j.ygyno.2009.06.028.CrossRefPubMed
16.
Hasselle MD, Rose BS, Kochanski JD, Nath SK, Bafana R, Yashar CM, Hasan Y, Roeske JC, Mundt AJ, Mell LK: Clinical outcomes of intensity-modulated pelvic radiation therapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 2011, 80: 1436-1445. 10.1016/j.ijrobp.2010.04.041.CrossRefPubMed
17.
Folkert MR, Shih KK, Abu-Rustum NR, Jewell E, Kollmeier MA, Makker V, Barakat RR, Alektiar KM: Postoperative pelvic intensity-modulated radiotherapy and concurrent chemotherapy in intermediate- and high-risk cervical cancer. Gynecol Oncol. 2013, 128 (2): 288-293. 10.1016/j.ygyno.2012.11.012.CrossRefPubMed
18.
Du XL, Tao J, Sheng XG, Lu CH, Yu H, Wang C, Song QQ, Li QS, Pan CX: Intensity-modulated radiation therapy for advanced cervical cancer: a comparison of dosimetric and clinical outcomes with conventional radiotherapy. Gynecol Oncol. 2012, 125 (1): 151-157. 10.1016/j.ygyno.2011.12.432.CrossRefPubMed
19.
Chen SW, Liang JA, Yang SN, Liu RT, Lin FJ: The prediction of late rectal complications following the treatment of uterine cervical cancer by high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys. 2000, 47 (4): 955-961. 10.1016/S0360-3016(00)00559-9.CrossRefPubMed
20.
Gondi V, Bentzen SM, Sklenar KL, Dunn EF, Petereit DG, Tannehill SP, Straub M, Bradley KA: Severe late toxicities following concomitant chemoradiotherapy compared to radiotherapy alone in cervical cancer: an inter-era analysis. Int J Radiat Oncol Biol Phys. 2012, 84 (4): 973-982. 10.1016/j.ijrobp.2012.01.064.CrossRefPubMedPubMedCentral
21.
Gadducci A, Sartori E, Maggino T, Zola P, Cosio S, Zizioli V, Lapresa M, Piovano E, Landoni F: Pathological response on surgical samples is an independent prognostic variable for patients with Stage Ib2-IIb cervical cancer treated with neoadjuvant chemotherapy and radical hysterectomy: An Italian multicenterretrospective study (CTF Study). Gynecol Oncol. 2013, 3: pii: S0090-8258(13)01203-1
22.
Minig L, Colombo N, Zanagnolo V, Landoni F, Bocciolone L, Cárdenas-Rebollo JM, Iodice S, Maggioni A: Platinum-based neoadjuvant chemotherapy followed by radical surgery for cervical carcinoma international federation of gynecology and obstetrics stage IB2-IIB. Int J Gynecol Cancer. 2013, [Epub ahead of print]
23.
Horn LC, Fischer U, Raptis G, Bilek K, Hentschel B: Tumor size is of prognostic value in surgically treated FIGO stage II cervical cancer. Gynecol Oncol. 2007, 107: 310-315. 10.1016/j.ygyno.2007.06.026.CrossRefPubMed
24.
Reig A, Membrive I, Foro P, Sanz X, Rodríguez N, Lozano J, Lacruz M, Quera J, Fernández-Velilla E, Algara M: Long-term results and prognostic factors of patients with cervical carcinoma treated with concurrent chemoradiotherapy. Clin Transl Oncol. 2011, 13 (7): 504-508. 10.1007/s12094-011-0688-8.CrossRefPubMed
25.
Xie XZ, Song K, Cui B, Jiang J, Zhang YZ, Wang B, Yang XS, Kong BH: Clinical and pathological factors related to the prognosis of Chinese patients with stage Ib to IIb cervical cancer. Asian Pac J Cancer Prev. 2012, 13 (11): 5505-5510. 10.7314/APJCP.2012.13.11.5505.CrossRefPubMed
26.
Galic V, Herzog TJ, Lewin SN, Neugut AI, Burke WM, Lu YS, Hershman DL, Wright JD: Prognostic significance of adenocarcinoma histology in women with cervical cancer. Gynecol Oncol. 2012, 125 (2): 287-291. 10.1016/j.ygyno.2012.01.012.CrossRefPubMed
Metadata
Title
Radical hysterectomy with adjuvant radiotherapy versus radical radiotherapy for FIGO stage IIB cervical cancer
Authors
Yanlan Chai
Tao Wang
Juan Wang
Yunyi Yang
Ying Gao
Jiyong Gao
Shangfeng Gao
Yueling Wang
Xi Zhou
Zi Liu
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-63

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Research article

Histological review of skin cancers in African Albinos: a 10-year retrospective review

Research article

BRAT1 deficiency causes increased glucose metabolism and mitochondrial malfunction

Debate

The biography of the immune system and the control of cancer: from St Peregrine to contemporary vaccination strategies

Research article

A phase II study of cisplatin with intravenous and oral vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy with oral vinorelbine and cisplatin for locally advanced non-small cell lung cancer

Research article

Emerging markers of cachexia predict survival in cancer patients

Research article

Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits